26 results on '"Geng, Mei-yu"'
Search Results
2. Antitumor pharmacological research in the era of personalized medicine
3. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
4. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma
5. CTC clusters induced by heparanase enhance breast cancer metastasis.
6. A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis
7. SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors
8. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells
9. Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3
10. Author Correction: G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin
11. Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R
12. Author Correction: Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
13. Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
14. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin
15. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma
16. SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors
17. PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment
18. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells
19. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression
20. Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer
21. Abstract 4680: H3K9 methyltransferase G9a epigenetically regulates breast cancer cell iron homeostasisviarepressing ferroxidase hephaestin expression, promotes breast cancer growth
22. Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration
23. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer
24. Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors
25. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo
26. One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody–drug conjugates
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.